Belvedere Trading’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Belvedere Trading’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,200	Closed	-$85.3K	–	889
2025 Q4	$85.3K	Buy	1,200 +500	+71%	+$68.7K	﹤0.01%	589
2025 Q3	$3.28K	Sell	700 -200	-22%	-$14.1K	﹤0.01%	841
2025 Q2	$2.56K	Sell	900 -1,500	-63%	-$79.6K	﹤0.01%	761
2025 Q1	$94.2K	Buy	2,400 +1,500	+167%	+$128K	﹤0.01%	436
2024 Q4	$4.05K	Buy	900 +100	+13%	+$11.8K	﹤0.01%	759
2024 Q3	$5.15K	Buy	800 +400	+100%	+$52.2K	﹤0.01%	664
2024 Q2	$2.27K	Sell	400 -1,000	-71%	-$107K	﹤0.01%	639
2024 Q1	$186K	Buy	+1,400	New	+$183K	﹤0.01%	353

Other funds holding LABU

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return

CBU

CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return

Belvedere Trading's LABU Position: Q2 2026 in Review

Belvedere Trading sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2026, closing a stake of 6,501 shares — an estimated $1.08M sold.

Belvedere Trading first reported a position in LABU in Q3 2022 and held it in 8 quarters. The position peaked at $1.08M in Q1 2026. 36 funds tracked by Wall St. Rank hold LABU as of Q2 2026.

Belvedere Trading reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2026 after selling out during the quarter.
Belvedere Trading sold 6,501 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2026, an estimated $1.08M.
Belvedere Trading first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2022 and held it in 8 quarters.
Belvedere Trading's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $1.08M in Q1 2026.
36 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.